Clinical Trial Update: Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating misoprostol and oxytocin delivered in Uniject for postpartum hemorrhage prevention in communities has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Hemorrhage

Drugs mentioned

• MISOPROSTOL (Misoprostol)
• Oxytocin (Oxytocin)

Snippet

Sponsor: Gynuity Health Projects | Conditions: Postpartum Hemorrhage | Phase 3 | Status: WITHDRAWN